Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 7-12

  Rogers, S L ^a   Cooper, N M ^b   Sukovaty, R ^b   Pederson, J E ^b   Lee, J N ^b   Friedhoff, L T ^a  

^a EISAI INC   (United States)

^b Harris Laboratories Inc Lincolnshire   (United States)

Author keywords

Alzheimer's disease; Donepezil; Pharmacodynamics; Pharmacokinetics; Selective acetylcholinesterase inhibitor

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; ERYTHROCYTE MEMBRANE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0032406418     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1007.x     Document Type: Article

References (17)

1. Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry, Sixth Edition. Baltimore, Maryland: Williams & Wilkins, 1995: 2562.
2. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J 1991; 5: 278-286.
3. Becker RE. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 1-30.
4. Taylor P. Anticholinesterase agents. In The Pharmacological Basis of Therapeutics, Eighth Edition, eds Gilman AG, Rall TW, Nies AS, Taylor P. New York: McGraw-Hill, 1993: 131-149.
5. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-1245.
6. Davis KL, Thal LJ, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-1259.
7. Stern Y, Sano M, Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988; 38: 1837-1841.
8. Watkins PB, Zimmerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
9. Cardozo MG, Iimura Y, Sugimoto Y, Yamanishi Y, Hopfinger AJ. QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of actylcholinesterase. J Med Chem 1992; 35: 584-589.
10. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analysis and molecular shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 590-601.
11. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Biorg Med Chem Lett 1992; 2: 871-876.
12. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase. Comparison with other inhibitors. In Basic, Clinical, and Therapeuntic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Fisher A, Yoshida M. New York: Plenum Press, 1990: 409-413.
13. Rogers SL, Yamansihi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
14. Ogura H, Kosasa T, Araki S, Yamanishi Y, Yamatsu K. Behavioral study of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc Neurosci Abstr 1988; 14: 60 (27.21).
15. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 1-6.
16. Lee JW, Rogers SL, Friedhoff IT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.
17. Hulse JD, Rogers SL, Friedhorff LT, Sukovaty R, Pedersen JE, Lee JW. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020). Pharm Res 1992; 9: S338.